Trial 2N-24-1


A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Other
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Kristy Sartor Massopust, Coordinator, Aida Lozada, Coordinator, Sreebharathy Venkatesh, D.M., Sana Mutalib, Coordinator, Anisa Sandin, Coordinator, Thomas Won, Coordinator, Bomi Choi, Coordinator, Marie-Laure Gollier, D.M., Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.